Modality
Cell Therapy
MOA
CAR-T BCMA
Target
SOS1
Pathway
Lipid Met
MCCIgAN
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
Aug 2017
→ Apr 2031
Phase 2Current
NCT04576696
2,395 pts·IgAN
2017-08→2028-05·Recruiting
NCT05487874
1,296 pts·IgAN
2022-06→2031-04·Active
3,691 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-156mo agoEMA Filing· MCC
2028-05-102.1y awayPh2 Data· IgAN
2031-04-175.0y awayPh2 Data· IgAN
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Recruit…
P2
Active
Catalysts
EMA Filing
2025-09-15 · 6mo ago
MCC
Ph2 Data
2028-05-10 · 2.1y away
IgAN
Ph2 Data
2031-04-17 · 5.0y away
IgAN
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04576696 | Phase 2 | IgAN | Recruiting | 2395 | EDSS |
| NCT05487874 | Phase 2 | IgAN | Active | 1296 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |